MedTrace Logo

Chemotherapy Followed by Irreversible Electroporation in Patients With Unresectable Locally Advanced Pancreatic Cancer

NCT04093141 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-01

No results posted yet for this study

Summary

This study is a single-arm clinical trial of irreversible electroporation (IRE) for the treatment of unresectable locally advanced pancreatic cancer (LAPC).

The aim of the study is to evaluate the efficacy of IRE in this patient group. A statistical analysis of patient survival will be performed, comparing study participants to historical data from the Danish national database of pancreatic cancer patients.

Conditions

  • Unresectable Pancreatic Cancer

Interventions

PROCEDURE

IRE

in situ irreversible electroporation

Sponsors & Collaborators

  • Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery

    lead OTHER

Principal Investigators

  • Ole Thorlacius-Ussing, Professor, DMSc · Department of gastrointestinal surgery, Aalborg University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2022-05-31
Completion
2024-05-31
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04093141 on ClinicalTrials.gov